NEW YORK (GenomeWeb) – Meridian Bioscience today announced that Health Canada has approved for marketing Meridian's molecular assays for Mycoplasma pneumonia and Bordetella pertussis on the company's illumigene platform.

The M. pneumonia test amplifies specific DNA to detect the bacterium and help patients receive appropriate treatment in a timely manner. The B. pertussis test similarly amplifies a specific DNA target to detect that bacterium. It uses nasopharyngeal swab samples and takes less than sixty minutes to report a result.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.